PRIMARY MYELOFIBROSIS
Clinical trials for PRIMARY MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for PRIMARY MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill aims to shrink spleens and ease symptoms in tough blood cancers
Disease control CompletedThis study tested an experimental pill called pelabresib, both alone and combined with an existing drug (ruxolitinib), for people with myelofibrosis and other blood cancers. The main goals were to find a safe dose and see if the treatment could reduce spleen size, ease symptoms l…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Two-Pronged attack on rare blood cancers shows promise in trial
Disease control CompletedThis study tested whether combining two existing drugs, ruxolitinib and azacytidine, could better control certain rare blood cancers. It involved 121 adults with myelofibrosis or similar conditions where the bone marrow doesn't work properly. The goal was to see if using both dru…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Extended trial tests blood cancer drug for ongoing safety
Disease control CompletedThis study followed patients with rare blood cancers called myeloproliferative neoplasms (MPNs) who had already been taking the experimental drug bomedemstat in previous trials. The goal was to check the long-term safety and effectiveness of continuing this daily oral medication.…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC